Physician profile
Namrata Sharma Goel
NPI 1497862247
$425,952.87
in general payments reported to CMS, 2019-2025
25 companies · $50K in 2025
The $50K reported for 2025 was more than what 98% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $550 · 2020: $2,578 · 2021: $16K · 2022: $89K · 2023: $144K · 2024: $124K · 2025: $50K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $113K · Honoraria: $103K · Travel and Lodging: $79K · Consulting Fee: $13K · Food and Beverage: $8,853 · Education: $73.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $112,962.50 |
| Honoraria | $103,090.00 |
| Travel and Lodging | $79,459.16 |
| Consulting Fee | $13,360.00 |
| Food and Beverage | $8,852.53 |
| Education | $73.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $249,229.57 | 2019-2023 | Krystexxa |
| Amgen INC. | $170,273.84 | 2019-2025 | Krystexxa, Tavneos |
| Sobi, INC | $2,380.39 | 2025 | |
| Vifor Pharma, INC. | $1,041.65 | 2019-2025 | Veltassa |
| Astrazeneca Pharmaceuticals Lp | $788.47 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $331.51 | 2021-2025 | |
| Ani Pharmaceuticals, INC. | $245.16 | 2025 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $227.00 | 2023-2025 | |
| Ardelyx, INC. | $213.14 | 2023-2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $195.88 | 2022-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $187.36 | 2019-2025 | Jynarque |
| Travere Therapeutics, INC. | $166.10 | 2022-2025 | Filspari |
| Fresenius USA Marketing, INC. | $139.79 | 2019-2024 | Velphoro |
| Philips North America LLC | $97.71 | 2022-2023 | |
| Mallinckrodt Enterprises LLC | $77.57 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $65.83 | 2021-2024 | Vafseo, Auryxia |
| Glaxosmithkline, LLC. | $56.30 | 2023-2024 | Benlysta |
| Aurinia Pharma U.S., INC. | $46.50 | 2022-2023 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $41.88 | 2021-2025 | Acthar |
| Daiichi Sankyo INC. | $36.83 | 2023 | Injectafer |
| Opko Pharmaceuticals, LLC | $34.80 | 2024 | Rayaldee |
| Abbott Laboratories | $22.68 | 2023 | Eterna |
| Lilly USA, LLC | $20.34 | 2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $18.40 | 2025 | Ultomiris |
| Novo Nordisk INC | $14.17 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Namrata Goel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.